Company Overview of New Haven Pharmaceuticals, Inc.
New Haven Pharmaceuticals, Inc. develops prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe active pharmaceutical ingredients for therapeutic applications. It offers NHP-554C, an anti-platelet aspirin product for patients at higher risk for a secondary stroke/acute cardiac event that slowly releases into the bloodstream over 24 hours; NHP-554CZ, an anti-platelet aspirin product incorporating Yale University technology utilizing zinc salts; and NHP-229 for the purpose of lowering stomach acid alone or in combination with other drugs. The company was founded in 2008 and is based in New Haven, Connecticut.
142 Temple Street
New Haven, CT 06510
Founded in 2008
Key Executives for New Haven Pharmaceuticals, Inc.
New Haven Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|Watson Laboratories Caribe Inc.||United States|
|Genemed Biotechnologies, Inc.||United States|
|ThoRx Laboratories, Inc.||United States|
|The Ritedose Corporation||United States|
|Achelios Therapeutics LLC||United States|
Recent Private Companies Transactions
October 8, 2014
January 30, 2014
To contact New Haven Pharmaceuticals, Inc., please visit www.newhavenpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.